Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Rituximab in Combination With Fludarabine and Cyclophosphamide for the Treatment of Relapsed Follicular Lymphoma

NCT00393107 is registered in ClinicalTrials.gov with Gruppo Italiano Studio Linfomi as lead sponsor.

NCT NCT00393107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00393107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Rituximab in Combination With Fludarabine and Cyclophosphamide for the Treatment of Relapsed Follicular Lymphoma
Lead sponsor
Gruppo Italiano Studio Linfomi
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2000
Completion date
August 31, 2006
Enrollment
54
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma